Author:
Tang Tiantian,Luo Xianzhang,Li Na,Li Qiaoqiao,Zhang Min,Zeng Jin,Song Haichi,Li Lixian,Chen Wanyi
Reference27 articles.
1. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer;Schlumberger;N Engl J Med.,2015
2. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial;Motzer;Lancet Oncol.,2015
3. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018
4. Clinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor;Hussein;Eur J Drug Metab Pharmacokinet.,2017
5. Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma;Nod;Cancer Chemother Pharmacol.,2021